# Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Source: https://onco.cc/trials/nct06534762/  
OnCo record `nct06534762` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Zhejiang Provincial People's Hospital, now recruiting.

## Summary

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study is a phase 2, interventional study registered as NCT06534762 by Zhejiang Provincial People's Hospital, with a registry enrolment figure of 260 participants, started 2024-07-15 and due to reach its primary completion in 2026-07-01. Interventions recorded: Mirabegron. Conditions listed: NSCLC; SCLC; Colorectal Cancer; Pancreas Cancer; TNBC - Triple-Negative Breast Cancer; DLBCL - Diffuse Large B Cell Lymphoma; Squamous Cell Carcinoma of Head and Neck. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06534762
- Phase: 2
- Setting: Efficacy and Safety of Milaberon in Combination With Standard Therapy in Advanced Solid Tumors: an Open, Multicenter, Clinical Study
- Sponsor: Zhejiang Provincial People's Hospital
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT06534762: https://clinicaltrials.gov/study/NCT06534762

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06534762.json